BridgeBio Pharma (NASDAQ:BBIO) Issues Quarterly Earnings Results

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22), Zacks reports. The firm had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million.

BridgeBio Pharma Stock Up 0.1 %

NASDAQ BBIO traded up $0.04 on Friday, hitting $36.85. 2,508,887 shares of the stock were exchanged, compared to its average volume of 2,933,085. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The company has a market cap of $6.96 billion, a PE ratio of -15.29 and a beta of 1.07. The company has a 50-day moving average price of $31.90 and a 200-day moving average price of $27.93.

Analyst Ratings Changes

BBIO has been the topic of a number of research analyst reports. Bank of America boosted their price target on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. Citigroup lifted their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday. Scotiabank lifted their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a report on Friday. Cantor Fitzgerald restated an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $51.67.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson sold 4,148 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,705,098.24. The trade was a 3.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the sale, the insider now owns 22,055,375 shares of the company's stock, valued at $769,732,587.50. This represents a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,496,239 shares of company stock worth $122,612,036 in the last 90 days. Corporate insiders own 24.66% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.